Researchers with the SWOG Cancer Research Network studied whether acupuncture could reduce joint pain caused by a common breast cancer treatment. Many women with early‑stage, hormone‑sensitive breast cancer take medications called aromatase inhibitors, often for five to ten years, to reduce the chance that their cancer will return. While these drugs are effective, up to half of patients experience significant joint pain and stiffness as a side effect, which can interfere with daily activities like walking, typing, or climbing stairs and may lead some women to stop taking their cancer medication.
The study, known as S1200, was the largest and most rigorous clinical trial of acupuncture for this problem. More than 200 women with breast cancer‑related joint pain were randomly assigned to receive true acupuncture, sham (placebo) acupuncture, or no acupuncture at all. Women who received true acupuncture had treatment sessions over several weeks, and their pain levels were measured using standard pain assessment tools. This design allowed researchers to determine whether benefits were due to acupuncture itself rather than expectation or placebo effects.
The results showed that acupuncture significantly reduced joint pain compared with both sham acupuncture and no treatment. More than half of the women who received true acupuncture experienced meaningful pain relief, and the improvements lasted for months after treatment ended. Women receiving sham acupuncture did not do better than those who received no treatment, strengthening the evidence that acupuncture itself – not just belief or attention – was responsible for the pain reduction.
These findings suggest that acupuncture is a safe, non‑drug option to help manage joint pain related to breast cancer therapy. By relieving pain without adding medications or opioids, acupuncture may help more women stay on their prescribed cancer treatment and maintain a better quality of life. The study highlights the importance of addressing side effects, not just cancer itself, to improve long‑term outcomes for breast cancer survivors.
